首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1547784

全球静脉免疫球蛋白市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Intravenous Immunoglobulin Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球静脉免疫球蛋白市场需求预计将从2023年的133亿美元达到2032年近270亿美元的市场规模，2024-2032年研究期间复合年增长率为8.19%。

静脉注射免疫球蛋白（IVIG）是一种有助于治疗抗体缺乏症患者的疗法。它是由数千名健康人血浆中的免疫球蛋白（抗体）製成的血液製品，用于对抗感染。免疫球蛋白是由浆细胞产生的醣蛋白。由于 IVIG 是由血浆製备的，因此高度纯化，因此发生血液传染的机会极低。这种疗法有助于治疗多种疾病，如川崎病、红斑性狼疮、格林巴利症候群、肌肉炎、慢性发炎性脱髓鞘性多发性神经病变（CIDP）以及免疫缺陷如免疫性血小板减少症。除此之外，它也用于治疗一些神经系统疾病，例如多发性硬化症或重症肌无力。

市场动态

全球静脉注射免疫球蛋白市场主要受到老年人口增长、免疫缺陷疾病高盛行率、血友病患者数量不断增加、IVIG治疗接受度增加以及静脉注射免疫球蛋白药物计画投资增加的推动。免疫缺陷症患者数量的增加是增加静脉免疫球蛋白治疗需求的主要因素。根据美国国家过敏和传染病研究所 (NIAID) 的数据，有超过 200 种不同形式的原发性免疫缺陷疾病 (PIDD)，在美国约有 50 万人患有此类 PIDD。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球静脉免疫球蛋白市场的每个细分市场进行了包容性评估。静脉免疫球蛋白产业的成长和趋势为本研究提供了整体方法。

市场区隔

静脉免疫球蛋白市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人口统计数据以及即将到来的机会。

按申请

低丙种球蛋白血症
CIPD
免疫缺乏疾病
先天性爱滋病
慢性淋巴球白血病
重症肌无力
多灶性运动神经病变
ITP
川崎病
格林巴利症候群
其他的

按配销通路

医院药房
专业药房
其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲静脉免疫球蛋白市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。静脉注射免疫球蛋白市场的主要参与者包括 Biotest AG、Baxter International Inc.、Octapharma AG、LFB Biotechnologies、Grifols SA、CSL Behring、China Biologics Products Inc.、Kedrion Biopharma、BDI Pharma Inc.。种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 8 章：静脉免疫球蛋白公司的竞争格局

静脉免疫球蛋白市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 9 章：公司简介

顶级公司市占率分析
市场集中度
Biotest AG

公司概况
公司收入
产品
最新动态

Baxter International Inc.

公司概况
公司收入
产品
最新动态

Octapharma AG

公司概况
公司收入
产品
最新动态

LFB Biotechnologies

公司概况
公司收入
产品
最新动态

Grifols SA

公司概况
公司收入
产品
最新动态

CSL Behring

公司概况
公司收入
产品
最新动态

China Biologics Products Inc.

公司概况
公司收入
产品
最新动态

Kedrion Biopharma

公司概况
公司收入
产品
最新动态

BDI Pharma Inc

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR11213403

The global demand for Intravenous Immunoglobulin Market is presumed to reach the market size of nearly USD 27 Billion by 2032 from USD 13.3 Billion in 2023 with a CAGR of 8.19% under the study period 2024-2032.

Intravenous Immunoglobulin (IVIG) refers to a therapy that helps in treating patients with antibody deficiencies. It is a blood product made by immunoglobulin's (antibodies) from the plasma of thousands of healthy people to fight infections. Immunoglobulin's are glycoprotein's which are produced from the plasma cells. As IVIG is prepared from plasma, it is highly purified so the chances of developing a blood-borne infection are exceptionally low. This therapy helps in treating a large number of diseases such as kawasaki disease, lupus, guillain-barre syndrome, myositis, chronic inflammatory demyelinating polyneuropathy (CIDP) and also immune deficiencies such as immune thrombocytopenia. In addition to this it is also used for treating some neurological diseases such as multiple sclerosis or myasthenia gravis.

MARKET DYNAMICS

The global Intravenous Immunoglobulin Market is majorly driven by growing elderly population, high prevalence of immunodeficiency diseases, growing number of hemophilic patients, increase in acceptance of IVIG treatments and rising investment in intravenous immunoglobulin medication projects. Increasing number of patients with immunodeficiency disorders is the major factor boosting the demand of Intravenous Immunoglobulin therapy. As per National Institute of Allergy and Infectious diseases (NIAID) there are over 200 different forms of primary immune deficiency diseases (PIDDs) and around 500,000 people in the United States suffering from such PIDDS.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Intravenous Immunoglobulin. The growth and trends of Intravenous Immunoglobulin industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Intravenous Immunoglobulin market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Hypogammaglobulinemia
CIPD
Immunodeficiency Diseases
Congenital AIDS
Chronic Lymphocytic Leukemia
Myasthenia Gravis
Multifocal Motor Neuropathy
ITP
Kawasaki Disease
Guillain-barre Syndrome
Others

By Distribution Channel

Hospital Pharmacy
Specialty Pharmacy
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Intravenous Immunoglobulin market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Intravenous Immunoglobulin market include Biotest AG, Baxter International Inc., Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, BDI Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. INTRAVENOUS IMMUNOGLOBULIN - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS BY APPLICATION

5.1. Overview By Application
5.2. Historical and Forecast Data
5.3. Analysis By Application
5.4. Hypogammaglobulinemia Historic and Forecast Sales By Regions
5.5. CIPD Historic and Forecast Sales By Regions
5.6. Immunodeficiency Diseases Historic and Forecast Sales By Regions
5.7. Congenital AIDS Historic and Forecast Sales By Regions
5.8. Chronic Lymphocytic Leukemia Historic and Forecast Sales By Regions
5.9. Myasthenia Gravis Historic and Forecast Sales By Regions
5.10. Multifocal Motor Neuropathy Historic and Forecast Sales By Regions
5.11. ITP Historic and Forecast Sales By Regions
5.12. Kawasaki Disease Historic and Forecast Sales By Regions
5.13. Guillain-barre Syndrome Historic and Forecast Sales By Regions
5.14. Others Historic and Forecast Sales By Regions

6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1. Overview By Distribution Channel
6.2. Historical and Forecast Data
6.3. Analysis By Distribution Channel
6.4. Hospital Pharmacy Historic and Forecast Sales By Regions
6.5. Specialty Pharmacy Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE INTRAVENOUS IMMUNOGLOBULIN COMPANIES

8.1. Intravenous Immunoglobulin Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF INTRAVENOUS IMMUNOGLOBULIN INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Biotest AG
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Baxter International Inc.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Octapharma AG
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. LFB Biotechnologies
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Grifols SA
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. CSL Behring
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. China Biologics Products Inc.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Kedrion Biopharma
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. BDI Pharma Inc
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments